Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: Performance of the transcription-mediated amplification assay

Journal of Viral Hepatitis

Volumn 15, Issue 1, 2008, Pages 66-70

  Ferraro, D ^a   Giglio, M ^a   Bonura, C ^a   Di Marco, V ^a   Mondelli, M U ^b   Craxi A ^a   Di Stefano, R ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Cattedra di Virologia   (Italy)

Author keywords

Antiviral therapy; EVR; HCV chronic hepatitis; HCV RNA; RT PCR; TMA

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; VIRUS DETECTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 36949021326     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00896.x     Document Type: Article

References (20)

1. Lee SC, Anisha A, Lee N et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse-transcription PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000 38 : 4171 4179.
2. Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005 9 (3 371 382.
3. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002 36 (Suppl. 1 S65 S73.
4. Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal 2001 15 : 308 313.
5. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999 37 : 1567 1569.
6. Gerotto M, Dal Pero F, Bortoletto G et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006 44 (1 83 87.
7. Bruno S, Cammà C, Di Marco V et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004 41 : 474 481.
8. Cammà C, Bruno S, Di Marco V et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006 43 : 64 71.
9. Sawyer L, Leung K, Friesenhahn M, Duey D, McMorrow M, Eguchi B. Clinical laboratory evaluation of a new sensitive and specific assay for qualitative detection of hepatitis C virus RNA in clinical specimens. J Hepatol 2000 32 (Suppl. 2 116A.
10. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003 23 (Suppl. 1 35 46.
11. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005 11 : 86 94.
12. Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol 2001 39 : 2850 2855.
13. Comanor L, Anderson F, Ghany M et al. Transcription-Mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001 96 : 2968 2972.
14. Sarrazin C. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. J Clin Virol 2002 25 : S23 S29.
15. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005 43 : 425 433.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
17. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. 2002-June 10-12, 2002. Hepatology 2002 36 : S3 S20.
18. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003 55 (4 360 367.
19. Young KC, Lindsay KL, Lee KJ et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003 38 : 869 878.
20. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37 (3 600 609.